Enanta Pharma Q2 2025 Update: Royalty Deal Highlighted
Ticker: ENTA · Form: 10-Q · Filed: May 14, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, royalty-agreement, financials
TL;DR
Enanta Q2 2025: R&D and G&A expenses detailed, royalty deal with Omers noted.
AI Summary
Enanta Pharmaceuticals Inc. reported its Q2 2025 results, ending March 31, 2025. The company's filing details financial activities including research and development expenses and general and administrative expenses for the period. Notably, the filing references the "Omers Royalty Purchase Agreement" related to the "Sale of Future Royalties" as of March 31, 2025.
Why It Matters
This filing provides insight into Enanta's financial health and ongoing operational expenses, crucial for understanding its drug development pipeline and potential future revenue streams.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Enanta faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $0.00 — Net Income (While not explicitly stated as a dollar amount, the absence of specific profit/loss figures suggests a focus on operational details rather than immediate profitability in this excerpt.)
- $0.00 — Revenue (Similar to Net Income, specific revenue figures are not detailed in this excerpt, indicating a focus on other financial aspects.)
Key Players & Entities
- Enanta Pharmaceuticals Inc. (company) — Filer
- Omers Royalty Purchase Agreement (company) — Royalty agreement
- 20250331 (date) — Reporting period end date
FAQ
What were Enanta's Research and Development expenses for the six months ended March 31, 2025?
The filing indicates that 'us-gaap:ResearchAndDevelopmentExpenseMember' is a category for the period '2024-10-01 2025-03-31', but the specific dollar amount is not provided in this excerpt.
What is the significance of the 'Omers Royalty Purchase Agreement'?
The filing mentions 'enta:OmersRoyaltyPurchaseAgreementMember' in relation to 'enta:SaleOfFutureRoyaltiesMember' as of '2025-03-31', suggesting a financial arrangement involving future royalties.
What was the company's fiscal year end?
Enanta Pharmaceuticals Inc.'s fiscal year ends on September 30 (0930).
What is Enanta's business address?
Enanta Pharmaceuticals Inc. is located at 4 KINGSBURY AVENUE, WATERTOWN, MA 02472.
What type of financial instruments are referenced regarding fair value inputs?
The filing references 'us-gaap:FairValueInputsLevel3Member' and 'us-gaap:FairValueInputsLevel1Member' for valuation purposes, and specifically mentions 'enta:SeriesOneNonConvertiblePreferredStockMember' and 'enta:MeasurementInputProbabilitiesOfPayoutMember'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding ENANTA PHARMACEUTICALS INC (ENTA).